Pamela Hawn, Pharm.D.

Senior Director, Medical Affairs
Invivyd, Inc.

Disclosure(s): Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-2035) Pharmacokinetics (PK) and Serum Virus Neutralizing Antibody (sVNA) Titers Following the 2^nd dose of Pemivibart in the Phase 3 CANOPY Trial
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT